Neumentum, Inc.

Neumentum, Inc. is a healthcare company focused on developing innovative non-opioid analgesic solutions that address the challenges of current pain management treatments, aiming to provide safer alternatives to traditional pain relief options. Founded in 2017 in Palo Alto, US, Neumentum, Inc. specializes in non-opioid pain management solutions.

The company has successfully raised funding through four deals, with the most recent being a Series A round in September 2021, securing USD 13. 30 mn, valuing the company at USD 101. 81 mn. The firm is co-founded by Joseph Pergolizzi and Scott Shively, who also serves as the CEO.

Neumentum, Inc. specializes in developing and commercializing innovative non-opioid analgesic solutions aimed at addressing the limitations of current pain management treatments. The company's core product offerings include four novel non-opioid products designed to effectively manage both acute and chronic pain, targeting pain pathways without the risks associated with opioids. Neumentum's products are marketed to healthcare professionals, including pain specialists and primary care physicians, as well as patients seeking safer pain relief alternatives, ensuring distribution across both U.

S. and international markets. Neumentum's revenue generation strategy is based on partnerships and direct sales to healthcare providers and institutions. The company engages in B2B transactions, supplying its non-opioid products to hospitals, clinics, and pharmacies.

Neumentum's pricing structure considers the competitive landscape of pharmaceutical products in pain management, incorporating wholesale pricing for distributors and retail prices for end-users. Their product pipeline is positioned for markets that prioritize safe, effective analgesic alternatives, aiming to establish a strong revenue stream and promote the adoption of non-opioid therapies in pain management. Neumentum, Inc. plans to utilize the USD 13.

30 mn raised in Series A funding to support the development and launch of new non-opioid products, with an emphasis on addressing unmet needs in pain management. The company is also exploring expansion into international markets, targeting regions with significant demand for safer pain relief alternatives, aiming for entry by the end of 2023. The recent funding will facilitate these initiatives, helping to establish a broader presence in the global pain management landscape.